CT Volume Measurement of Hepatocellular Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)
Eligibility criteria
Qualifiers
Adult patients (≥18 years) with a confirmed diagnosis of HCC based on AASLD or EASL criteria.
Patients deemed unresectable by the multidisciplinary tumor board.
Patients scheduled for TACE as the primary locoregional therapy.
Preserved liver function (Child-Pugh class A or B).
Disqualifiers
Patients with extrahepatic metastases or portal vein thrombosis.
Patients with contraindications to iodinated contrast or TACE.
Patients with severe comorbid illness that precludes participation.
Patients refuse to provide informed consent.
Trial design
Treatments tested in this trial
- Ct
Treatment groups
No treatment groups listed
Locations
This trial has no locations
Sponsors and collaborators
Assiut University
Lead sponsor
Source ClinicalTrials.gov